230 related articles for article (PubMed ID: 16188028)
1. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma.
Théoleyre S; Mori K; Cherrier B; Passuti N; Gouin F; Rédini F; Heymann D
BMC Cancer; 2005 Sep; 5():123. PubMed ID: 16188028
[TBL] [Abstract][Full Text] [Related]
2. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma.
Zhou X; Wu J; Duan C; Liu Y
J Immunol Res; 2020; 2020():7890985. PubMed ID: 33062726
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
5. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
6. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
Schiltz PM; Beutel LD; Nayak SK; Dillman RO
J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
[TBL] [Abstract][Full Text] [Related]
7. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.
Turcotte S; Gros A; Hogan K; Tran E; Hinrichs CS; Wunderlich JR; Dudley ME; Rosenberg SA
J Immunol; 2013 Sep; 191(5):2217-25. PubMed ID: 23904171
[TBL] [Abstract][Full Text] [Related]
8. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Giordano G; Merlini A; Ferrero G; Mesiano G; Fiorino E; Brusco S; Centomo ML; Leuci V; D'Ambrosio L; Aglietta M; Sangiolo D; Grignani G; Pignochino Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831119
[TBL] [Abstract][Full Text] [Related]
9. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.
Rivoltini L; Arienti F; Orazi A; Cefalo G; Gasparini M; Gambacorti-Passerini C; Fossati-Bellani F; Parmiani G
Cancer Immunol Immunother; 1992; 34(4):241-51. PubMed ID: 1311218
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
Friedman KM; Prieto PA; Devillier LE; Gross CA; Yang JC; Wunderlich JR; Rosenberg SA; Dudley ME
J Immunother; 2012 Jun; 35(5):400-8. PubMed ID: 22576345
[TBL] [Abstract][Full Text] [Related]
12. High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement.
Pandolfino MC; Labarrière N; Tessier MH; Cassidanius A; Bercegeay S; Lemarre P; Dehaut F; Dréno B; Jotereau F
Cancer Immunol Immunother; 2001 May; 50(3):134-40. PubMed ID: 11419180
[TBL] [Abstract][Full Text] [Related]
13. Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors.
Shimizu Y; Iwatsuki S; Herberman RB; Whiteside TL
Int J Cancer; 1990 Nov; 46(5):878-83. PubMed ID: 2146230
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
16. Osteosarcoma: current status of immunotherapy and future trends (Review).
Mori K; Rédini F; Gouin F; Cherrier B; Heymann D
Oncol Rep; 2006 Mar; 15(3):693-700. PubMed ID: 16465432
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tumor-infiltrating lymphocytes in osteosarcomas of the jaws: a multicenter study.
Alves PM; de Arruda JAA; Arantes DAC; Costa SFS; Souza LL; Pontes HAR; Fonseca FP; Mesquita RA; Nonaka CFW; Mendonça EF; Batista AC
Virchows Arch; 2019 Feb; 474(2):201-207. PubMed ID: 30483955
[TBL] [Abstract][Full Text] [Related]
18. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
[TBL] [Abstract][Full Text] [Related]
19. Is Surgical Resection of the Primary Site Associated with an Improved Overall Survival for Patients with Primary Malignant Bone Tumors Who Have Metastatic Disease at Presentation?
Malik AT; Alexander JH; Mayerson JL; Khan SN; Scharschmidt TJ
Clin Orthop Relat Res; 2020 Oct; 478(10):2284-2295. PubMed ID: 32667758
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]